Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
Status:
Completed
Trial end date:
2018-04-25
Target enrollment:
Participant gender:
Summary
The study will compare the efficacy and safety of oral rivaroxaban and subcutaneous
dalteparin in patients with cancer associated thrombosis. It is designed as a non-inferiority
open label randomized multicenter trial with blinded adjudication of outcome events.